Clinical Trial

Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer

Name: Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer — clinical trial record (NCT07184021)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: No Acronym

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate the feasibility, safety, and pathological response of dose-dense neoadjuvant gemcitabine and cisplatin in patients with muscle-invasive bladder cancer, with the goal of improving tumor downstaging and optimizing outcomes before radical cystectomy.

Trial Details

NCT Number	NCT07184021
Lead Sponsor	Assiut University
Conditions	Urinary Bladder Cancer
Enrollment	30 participants
Start Date	2025-09
Primary Completion	2027-09 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2025-09-19